TP53 and neoplasm: Though these studies have shown that TAp73 can bind to the target promoters containing p53RE under experimental conditions and lead to cell cycle arrest and apoptosis, p53-null cells do not generally utilize the often un-mutated endogenous TAp73 to enforce tumor suppression, or to activate p53 target genes by default.